Lars Petter Jordheim
Université Lyon 1
ISPB, Lyon, 69003
France
Name/email consistency: high
- Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868. Jordheim, L.P., Plesa, A., Dreano, M., Cros-Perrial, E., Keime, C., Herveau, S., Demangel, D., Vendrell, J.A., Dumontet, C. Cancer Chemother. Pharmacol. (2011)
- Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53. Jordheim, L.P., Nguyen-Dumont, T., Thomas, X., Dumontet, C., Tavtigian, S.V. Drug Metab. Dispos. (2008)
- Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Jordheim, L.P., Dumontet, C. Biochim. Biophys. Acta (2007)
- Recent developments to improve the efficacy of cytotoxic nucleoside analogues. Jordheim, L.P., Galmarini, C.M., Dumontet, C. Recent. Pat. Anticancer. Drug. Discov (2006)
- Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells. Jordheim, L.P., Galmarini, C.M., Dumontet, C. Cancer Chemother. Pharmacol. (2006)
- F-ara-AMP is a substrate of cytoplasmic 5'-nucleotidase II (cN-II): HPLC and NMR studies of enzymatic dephosphorylation. Jordheim, L.P., Cros, E., Galmarini, C.M., Dumontet, C., Bretonnet, A.S., Krimm, I., Lancelin, J.M., Gagnieu, M.C. Nucleosides. Nucleotides. Nucleic. Acids (2006)
- Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Jordheim, L.P., Guittet, O., Lepoivre, M., Galmarini, C.M., Dumontet, C. Mol. Cancer Ther. (2005)
- Drug resistance to cytotoxic nucleoside analogues. Jordheim, L., Galmarini, C.M., Dumontet, C. Curr. Drug. Targets (2003)